Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Maria Eriksson-Lepkowska"'
Autor:
Gunnar Fager, Maria Eriksson-Lepkowska, Ulf Eriksson, Pia Ottosson, Per-Ola Attman, Ola Samuelsson
Publikováno v:
Nephrology Dialysis Transplantation. 20:1889-1897
Background This study assessed the feasibility of replacing intravenous (i.v.) dalteparin with the direct thrombin inhibitor (DTI) melagatran administered via dialysis fluid in patients undergoing haemodialysis, and also examined the pharmacokinetics
Autor:
Troy C. Sarich, Stig L. Boström, Karin Wåhlander, Michael Wolzt, Ulf G. Eriksson, Margareta Elg, Jeffrey I. Weitz, Marcel Levi, Mia Svensson, Maria Eriksson-Lepkowska
Publikováno v:
Thrombosis and haemostasis, 91(6), 1090-1096. Schattauer GmbH
SummaryThe objectives were to investigate whether activation of the extrinsic coagulation cascade by recombinant factor VIIa (rFVIIa) reverses the inhibition of thrombin generation and platelet activation by melagatran, the active form of the oral di
Autor:
Ulf Eriksson, Troy C. Sarich, Karin Wåhlander, Lis Ohlsson, Juan J. Badimon, Maria Eriksson-Lepkowska, Stefan Carlsson, Gunnar Fager, Julio I. Osende, David Gustafsson
Publikováno v:
Journal of Thrombosis and Haemostasis. 1:999-1004
Summary. Background: Thrombin plays a major role in thrombus formation through activation of platelets and conversion of fibrinogen to fibrin. Objectives: To investigate the antithrombotic effects of the oral direct thrombin inhibitor (DTI) ximelagat
Autor:
Björn Bake, Annhild Larsson, Ulf E. Jonsson, Maria Eriksson-Lepkowska, Magne Alpsten, Bertil Abrahamsson
Publikováno v:
Journal of Controlled Release. 52:301-310
The aim of the present study was to compare the bioavailability of nifedipine when administered as a hydrophilic matrix tablet (ER) and a push–pull osmotic pump tablet (XL) administrated after fasting, and to evaluate the effect of food for the hyd
Autor:
Inge Kalies, Margareta Elg, Maria Eriksson-Lepkowska, Anders Bylock, Troy C. Sarich, Per Nyström, Ulf Eriksson, Juan J. Badimon, Karin Wåhlander
Publikováno v:
Thrombosis and haemostasis. 95(3)
SummaryIt was the objective of this study to compare the antithrombotic effects and bleeding profiles of the oral direct thrombin inhibitor ximelagatran, an anticoagulant, and the antiplatelet agent clopidogrel on top of steady-state acetylsalicylic
Publikováno v:
Clinical pharmacokinetics. 42(8)
Background: The oral direct thrombin inhibitor ximelagatran is a new class of anticoagulant currently in clinical development for the prevention and treatment of thromboembolic disease. After oral administration, ximelagatran is rapidly absorbed and
Autor:
Lars Frison, Susanne Johansson, Eva Bredberg, Maria Eriksson-Lepkowska, Marita Larsson, Ulf G. Eriksson, Tommy B. Andersson, Annelie Thuresson
Publikováno v:
Clinical pharmacokinetics. 42(8)
Background: Ximelagatran is an oral direct thrombin inhibitor currently in clinical development for the prevention and treatment of thromboembolic disorders. After oral administration, ximelagatran is rapidly absorbed and extensively bioconverted, vi
Publikováno v:
European journal of clinical pharmacology. 59(4)
The aim of this study was to evaluate the effect of acetylsalicylic acid (ASA or aspirin) on the pharmacokinetics (PK) and pharmacodynamics (PD) of melagatran in healthy volunteers. Melagatran is the active form of the oral direct thrombin inhibitor,
Autor:
Per-Ola Attman, Pia Ottosson, Ola Samuelsson, Ulf G. Eriksson, Maria Eriksson-Lepkowska, Gunnar Fager
Publikováno v:
Nephrology Dialysis Transplantation; Sep2005, Vol. 20 Issue 9, p1889-1897, 9p